TRINETRA › Sectors › Healthcare
Poly Medicure Limited (POLYMED) — share price, P/E and fundamentals
Poly Medicure Limited (NSE: POLYMED) closed at ₹1,449.50 on 30 Oct 2026, -23.9% over one year, against a 52-week range of ₹1,182.00 – ₹2,094.30.
In the quarter ended 30 Jun 2026 (consolidated, filed 7 Aug 2026) it reported revenue of ₹525 cr and net profit of ₹86 cr, a 16.4% net margin; revenue grew 30.3% and profit fell 4.8% year on year.
On four consecutive filed quarters its trailing P/E is 46.6; since 7 May 2025 its own P/E has ranged from 34.9 to 83.1 (median 54.5), and today's reading is higher than 24% of those 367 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 11.1%, ROCE 14.6%, debt-to-equity 0.11, Piotroski F-score 4 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 60% of 63 sector peers; PBT margin higher than 65% of 63 sector peers; ROE higher than 32% of 63 sector peers.
Key figures
| Last close | ₹1,449.50 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -15.5% / +2.5% / -23.9% |
| 52-week low – high | ₹1,182.00 – ₹2,094.30 |
| Market capitalisation | ₹14,692 cr |
| Trailing P/E | 46.6 |
| Price / book | 4.73 |
| EV / EBITDA | 26.5 |
| Earnings yield | 2.1% |
| TTM EPS | ₹31.09 |
| TTM net profit | ₹315 cr |
| Quarter revenue | ₹525 cr |
| Quarter net profit | ₹86 cr |
| Net margin | 16.4% |
| Revenue growth (YoY) | +30.3% |
| Profit growth (YoY) | -4.8% |
| Return on equity | 11.1% |
| ROCE | 14.6% |
| Debt / equity | 0.11 |
| Current ratio | 3.37 |
| Free cash flow | ₹-68 cr |
| Piotroski F-score | 4 / 9 |
| Average daily turnover (50 days) | ₹16.7 cr |
Against Healthcare peers
| Metric | POLYMED | Peer median | Percentile |
|---|---|---|---|
| Net margin | 16.37 | 12.67 | 60 |
| PBT margin | 22.03 | 17.57 | 65 |
| ROE | 11.08 | 13.87 | 32 |
| ROCE | 14.63 | 17.26 | 35 |
| Debt / equity | 0.11 | 0.11 | 51 |
| Cash conversion | 0.75 | 1.25 | 16 |
| Trailing P/E | 46.63 | 43.07 | 54 |
| P/B | 4.73 | 6.02 | 39 |
Questions
What is the P/E ratio of Poly Medicure Limited?
Poly Medicure Limited's trailing P/E is 46.6, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 7 May 2025 its P/E has ranged 34.9–83.1.
What were Poly Medicure Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Poly Medicure Limited reported revenue of ₹525 cr and net profit of ₹86 cr (consolidated), filed with the exchange on 7 Aug 2026.
What is Poly Medicure Limited's ROE?
Return on equity is 11.1% based on the balance sheet dated 31 Mar 2026.
Does Poly Medicure Limited have debt?
Debt-to-equity is 0.11 on the balance sheet dated 31 Mar 2026.
What is POLYMED's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, POLYMED traded between ₹1,182.00 and ₹2,094.30.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.